Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

Exclusion Criteria

• •Eastern Cooperative Oncology Group (ECOG) questionnaire score of ≥3
• •Currently pregnant or planning on being pregnant within the study period.
• •Currently taking Momelotinib or Pacritinib (these agents are purported to reduce hepcidin).
• •Currently taking any of the contraindicated medications to Nelfinavir listed in section 13.2
• •Currently breastfeeding.
• •Known uncontrolled active viral or bacterial infection.
• •Known HIV+
• •Significant impairment of major organ or hematopoietic function defined as
• •1. Serum creatinine clearance less than 30 ml/min (eGFR).
• •2. Bilirubin more than 1.5 mg/dl except for Gilbert's disease. ALT or AST more than 2X upper normal limit or has radiologic evidence of liver cirrhosis.
• •3. Platelets \< 50 × 10\^9/L without transfusions
• •4. ANC \< 0.75 × 10\^9/L without growth factors
• •Known history of allergic reaction to nelfinavir.